• Something wrong with this record ?

Inhibition of TRPA1 and IL-6 signal alleviates neuropathic pain following chemotherapeutic bortezomib

D. Liu, M. Sun, D. Xu, X. Ma, D. Gao, H. Yu

. 2019 ; 68 (5) : 845-855. [pub] 20190819

Language English Country Czech Republic

Document type Journal Article

Persistent link   https://www.medvik.cz/link/bmc20005491

Bortezomib (BTZ) is used as a chemotherapeutic agent for the treatment of multiple myeloma. Nevertheless, one of the significant limiting complications of BTZ is painful peripheral neuropathy during BTZ therapy. Thus, in this study we examined signaling pathways of interleukin-6 (IL-6) and transient receptor potential ankyrin 1 (TRPA1) in the sensory nerves responsible for neuropathic pain induced by BTZ and further determined if influencing the pathways can improve neuropathic pain. ELISA and western blot analysis were used to examine the levels of IL-6, and IL-6 receptor (IL-6R), TRPA1 and p38-MAPK and JNK signal in the lumbar dorsal root ganglion. Behavioral test was performed to determine mechanical and cold sensitivity in a rat model. Our results showed that systemic injection of BTZ increased mechanical pain and cold sensitivity as compared with control animals. Data also showed that protein expression of TRPA1 and IL-6R was upregulated in the dorsal root ganglion of BTZ rats and blocking TRPA1 attenuated mechanical and cold sensitivity in control rats and BTZ rats. Notably, the inhibitory effect of blocking TRPA1 was smaller in BTZ rats than that in control rats. In addition, a blockade of IL-6 signal attenuated intracellular p38-MAPK and JNK in the sensory neuron. This also decreased TRPA1 expression and alleviated mechanical hyperalgesia and cold hypersensitivity in BTZ rats. In conclusion, we revealed specific signaling pathways leading to neuropathic pain induced by chemotherapeutic BTZ, including IL-6-TRPA1, suggesting that blocking these signals is beneficial to alleviate neuropathic pain during BTZ intervention.

References provided by Crossref.org

Bibliography, etc.

Literatura

000      
00000naa a2200000 a 4500
001      
bmc20005491
003      
CZ-PrNML
005      
20200527142047.0
007      
ta
008      
200511s2019 xr d f 000 0|eng||
009      
AR
024    7_
$a 10.33549/physiolres.934015 $2 doi
035    __
$a (PubMed)31424261
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xr
100    1_
$a Liu, D. $u Tumor Center, The First Hospital of Jilin University, Changchun, Jilin, China
245    10
$a Inhibition of TRPA1 and IL-6 signal alleviates neuropathic pain following chemotherapeutic bortezomib / $c D. Liu, M. Sun, D. Xu, X. Ma, D. Gao, H. Yu
504    __
$a Literatura
520    9_
$a Bortezomib (BTZ) is used as a chemotherapeutic agent for the treatment of multiple myeloma. Nevertheless, one of the significant limiting complications of BTZ is painful peripheral neuropathy during BTZ therapy. Thus, in this study we examined signaling pathways of interleukin-6 (IL-6) and transient receptor potential ankyrin 1 (TRPA1) in the sensory nerves responsible for neuropathic pain induced by BTZ and further determined if influencing the pathways can improve neuropathic pain. ELISA and western blot analysis were used to examine the levels of IL-6, and IL-6 receptor (IL-6R), TRPA1 and p38-MAPK and JNK signal in the lumbar dorsal root ganglion. Behavioral test was performed to determine mechanical and cold sensitivity in a rat model. Our results showed that systemic injection of BTZ increased mechanical pain and cold sensitivity as compared with control animals. Data also showed that protein expression of TRPA1 and IL-6R was upregulated in the dorsal root ganglion of BTZ rats and blocking TRPA1 attenuated mechanical and cold sensitivity in control rats and BTZ rats. Notably, the inhibitory effect of blocking TRPA1 was smaller in BTZ rats than that in control rats. In addition, a blockade of IL-6 signal attenuated intracellular p38-MAPK and JNK in the sensory neuron. This also decreased TRPA1 expression and alleviated mechanical hyperalgesia and cold hypersensitivity in BTZ rats. In conclusion, we revealed specific signaling pathways leading to neuropathic pain induced by chemotherapeutic BTZ, including IL-6-TRPA1, suggesting that blocking these signals is beneficial to alleviate neuropathic pain during BTZ intervention.
650    _2
$a acetanilidy $x farmakologie $7 D000083
650    _2
$a analgetika $x farmakologie $7 D000700
650    _2
$a zvířata $7 D000818
650    12
$a bortezomib $7 D000069286
650    _2
$a modely nemocí na zvířatech $7 D004195
650    _2
$a spinální ganglia $x metabolismus $x patofyziologie $x účinky léků $7 D005727
650    _2
$a interleukin-6 $x antagonisté a inhibitory $x metabolismus $7 D015850
650    _2
$a JNK mitogenem aktivované proteinkinasy $x metabolismus $7 D048031
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a neuralgie $x chemicky indukované $x farmakoterapie $x metabolismus $x patofyziologie $7 D009437
650    _2
$a práh bolesti $x účinky léků $7 D017288
650    _2
$a fosforylace $7 D010766
650    12
$a inhibitory proteasomu $7 D061988
650    _2
$a puriny $x farmakologie $7 D011687
650    _2
$a pyraziny $x farmakologie $7 D011719
650    _2
$a chinoxaliny $x farmakologie $7 D011810
650    _2
$a potkani Sprague-Dawley $7 D017207
650    _2
$a receptory interleukinu-6 $x antagonisté a inhibitory $x metabolismus $x účinky léků $7 D019947
650    _2
$a nervové receptory $x metabolismus $x účinky léků $7 D011984
650    _2
$a signální transdukce $7 D015398
650    _2
$a kationtový kanál TRPA1 $x antagonisté a inhibitory $x metabolismus $7 D000074025
650    _2
$a mitogenem aktivované proteinkinasy p38 $x metabolismus $7 D048051
655    _2
$a časopisecké články $7 D016428
700    1_
$a Sun, M. $u Tumor Center, The First Hospital of Jilin University, Changchun, Jilin, China
700    1_
$a Xu, D. $u Tumor Center, The First Hospital of Jilin University, Changchun, Jilin, China
700    1_
$a Ma, X. $u Tumor Center, The First Hospital of Jilin University, Changchun, Jilin, China
700    1_
$a Gao, D. $u Department of Otorhinolaryngology, The First Hospital of Jilin University, Changchun, Jilin, China
700    1_
$a Yu, H. $u Department of Otorhinolaryngology, The First Hospital of Jilin University, Changchun, Jilin, China
773    0_
$w MED00003824 $t Physiological research $x 1802-9973 $g Roč. 68, č. 5 (2019), s. 845-855
856    41
$u https://pubmed.ncbi.nlm.nih.gov/31424261 $y Pubmed
910    __
$a ABA008 $b A 4120 $c 266 $y p $z 0
990    __
$a 20200511 $b ABA008
991    __
$a 20200527094102 $b ABA008
999    __
$a ok $b bmc $g 1528592 $s 1095546
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2019 $b 68 $c 5 $d 845-855 $e 20190819 $i 1802-9973 $m Physiological research $n Physiol. Res. (Print) $x MED00003824
LZP    __
$b NLK118 $a Pubmed-20200511

Find record

Citation metrics

Archiving options